Cargando…
Precision medicine in acute lymphoblastic leukemia
The cure rate of childhood acute lymphoblastic leukemia (ALL) has exceeded 90% in some contemporary clinical trials. However, the dose intensity of conventional chemotherapy has been pushed to its limit. Further improvement in outcome will need to rely more heavily on molecular therapeutic as well a...
Autor principal: | Pui, Ching-Hon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671279/ https://www.ncbi.nlm.nih.gov/pubmed/33074527 http://dx.doi.org/10.1007/s11684-020-0759-8 |
Ejemplares similares
-
Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia
por: Inaba, Hiroto, et al.
Publicado: (2021) -
Personalized therapy in pediatric high-risk B-cell acute lymphoblastic leukemia
por: Karol, Seth E., et al.
Publicado: (2020) -
International Collaboration to Save Children With Acute Lymphoblastic Leukemia
por: Pui, Ching-Hon, et al.
Publicado: (2019) -
Toward the Cure of Acute Lymphoblastic Leukemia in Children in China
por: Chen, Si-Liang, et al.
Publicado: (2021) -
Modeling Mechanisms of In Vivo Variability in Methotrexate Accumulation and Folate Pathway Inhibition in Acute Lymphoblastic Leukemia Cells
por: Panetta, John C., et al.
Publicado: (2010)